Your Health, We Care
Release date: 2024-08-08 17:10:48 Recommended: 131
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-competitive properties, which can significantly inhibit the proliferation and migration ability of c-Met-dependent tumor cells, effectively induce apoptosis in these cells, and achieve anti-tumor activity.
In the GEOMETRY mono-1 study, the following results were shown for the treatment of metastatic non-small cell lung cancer (NSCLC) with MET Exon 14 skipping alterations in treatment-naïve and previously treated patients.
For treatment-naïve patients, the total response rate (ORR) was a significant 68%, a result that demonstrated good treatment responsiveness. Of these 68% of patients, 5% achieved complete remission, meaning that the symptoms and signs of the disease have completely disappeared and the best treatment outcome has been achieved. The remaining 63% achieved partial remission and partial improvement.
The ORR of previously treated patients was 44%, of which no patients achieved a complete response, and only 44% of patients achieved a partial response, showing a clear advantage in efficacy in treatment-naïve patients.
The median DOR of treatment-naïve patients was 16.6 months, and most patients were able to maintain a longer treatment effect. Forty-nine percent of treatment-naïve patients had a DOR of more than 12 months, indicating that these patients were able to benefit from treatment for a long time and their disease remained stable or continued to improve.
For previously treated patients, the median DOR was shortened to 9.7 months, and only 36% of patients achieved a DOR of 12 months or more, reaffirming the advantage of durable efficacy in treatment-naïve patients.
A series of adverse reactions may also occur during the use of capmatinib, the severity of these adverse reactions varies from person to person, and according to the drug label, the common adverse reactions are as follows:
This is one of the most common adverse effects and is manifested by abnormal fluid retention and swelling in certain parts of the body (e.g., face, hands, feet, ankles, etc.). Peripheral edema may cause discomfort to the patient, limit daily activities, and may be accompanied by pain or tightness.
Nausea is a strong feeling of upset in the stomach that is often accompanied by the urge to vomit. This discomfort can occur at any time and is usually more pronounced before or after eating. Nausea not only affects appetite but may also interfere with the patient's emotional state and sleep quality.
[Warm tips] Patients should maintain a positive attitude when using capmatinib and follow the doctor's advice for medication and monitoring.
